Craig-Hallum raised its price target for Exact Sciences to $127 from $115 following “exceptional” Q2 results.

Exact Sciences (EXAS) delivered a major preannounced Q2 beat and raise as well as a $2.8B buyout offer for Genomic Health (GHDX).

Twiggs Money Flow has exploded higher and large players volume has surged too on the preannnounced Q2 beat. Prices have been consolidating lately. There is a very little resistance above the current price. There is a support zone below the current price at $116.99, a stop order could be placed below this zone.

Prices have been consolidating lately. There is a very little resistance above the current price. There is a support zone below the current price at $116.99, a stop order could be placed below this zone.

Exact Sciences does not meet the requirements for an addition to the GST Portfolio but a short-term swing trade may be available, just keep a tight stop on it if you go for it.

Disclosure: I have no position in EXAS.

Exact Sciences News